{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032187","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.437016+00:00","generated_at":"2026-06-21T19:17:47.225224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed","bullets":["Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.","Adjusted EBITDA positive $0.1M vs -$0.2M prior year; loss from continuing ops $1.3M.","Cash balance $6.3M (up from $3.2M); sale of Pharma business removed going concern.","ThyGeNEXT pricing change reduced revenue and EBITDA by ~$1.4M in Q3.","Nine-month revenue $23.5M (-2%); loss from continuing ops improved to -$4.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032187","json":"https://secwatch.observer/filing/0001493152-22-032187.json","markdown":"https://secwatch.observer/filing/0001493152-22-032187.md","text":"https://secwatch.observer/filing/0001493152-22-032187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/0001493152-22-032187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:17:47.225224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2c68ad3d4ca56b88f75c419e41f80eb07d792bc","claim":"INTERPACE BIOSCIENCES, INC. reported the quarter ended September 30, 2022 results: revenue $8.2 million.","evidence_excerpt":"Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern ● Q3 Revenue of $8.2 million up 2% versus Prior Year ● Q3 Adjusted EBITDA Positive ● Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, November 14, 2022 (GLOBE NEWSWIRE)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032187/0001493152-22-032187-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$8.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}